8-K 1 f90878e8vk.htm FORM 8-K e8vk
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 11, 2003

ONYX PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)
     
0-28298   94-3154463
 
(Commission File No.)   (IRS Employer Identification No.)

3031 Research Drive
Richmond, California 94806

(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (510) 222-9700

 

ITEM 5. OTHER EVENTS
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS
SIGNATURES
EXHIBIT INDEX
Exhibit 99.1

Table of Contents

ITEM 5. OTHER EVENTS

     On June 11, 2003, Onyx Pharmaceuticals, Inc. announced that it is further prioritizing the development of BAY 43-9006, a novel small molecule anticancer compound in co-development with Bayer Pharmaceuticals Corporation. In connection with this change in priority, Onyx is restructuring its operations and will discontinue its therapeutic virus program. This restructuring will result in a reduction in force of approximately 50 of Onyx’s employees, most of whom were dedicated to the virus program. Onyx’s remaining scientific and administrative personnel will be focused on furthering the development of BAY 43-9006. The press release issued by Onyx Pharmaceuticals, dated June 11, 2003, titled “Onyx To Focus Exclusively on Small Molecule Cancer Program: BAY 43-9006 Takes Priority as Therapeutic Virus Program is Discontinued,” is attached hereto as Exhibit 99.1.

ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS

(c) Exhibits

     
Exhibit Number   Description
 
99.1   Press Release titled “Onyx To Focus Exclusively on Small Molecule Cancer Program: BAY 43-9006 Takes Priority as Therapeutic Virus Program is Discontinued,” dated June 11, 2003

 

Table of Contents

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
    ONYX PHARMACEUTICALS, INC. (Registrant)
   
Dated: June 12, 2003   By:   /s/ Hollings C. Renton
       
        Hollings C. Renton
Chairman of the Board,
President and Chief Executive Officer
   
Dated: June 12, 2003   By:   /s/ Marilyn E. Wortzman
       
        Marilyn E. Wortzman
Vice President, Finance

 

Table of Contents

EXHIBIT INDEX

     
Number   Description
 
99.1   Press release titled “Onyx To Focus Exclusively on Small Molecule Cancer Program: BAY 43-9006 Takes Priority as Therapeutic Virus Program is Discontinued,” dated June 11, 2003